Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

11/12/24 10:32:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MLTX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 MOONLAKE IMMUNOTHERAPEUTICS CLASS A COMMON STOCK Cusip #61559X104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61559X104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,938,963 Item 6: 0 Item 7: 4,941,124 Item 8: 0 Item 9: 4,941,124 Item 11: 7.856% Item 12: HC Cusip #61559X104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,941,124 Item 8: 0 Item 9: 4,941,124 Item 11: 7.856% Item 12: IN Item 1(a). Name of Issuer: MOONLAKE IMMUNOTHERAPEUTICS Item 1(b). Address of Issuer's Principal Executive Offices: DORFSTRASSE 29 ZUG, 6300 Switzerland Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 61559X104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,941,124 (b) Percent of Class: 7.856% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,941,124 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS. No one other person's interest in the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $MLTX alert in real time by email

Recent Analyst Ratings for

$MLTX

Date	Price Target	Rating	Analyst
11/3/2025	$30.00	Neutral → Buy	H.C. Wainwright
10/2/2025		Buy → Neutral	H.C. Wainwright
10/1/2025	$7.00	Buy → Neutral	Goldman
9/30/2025	$2.00	Outperform → Underperform	Wolfe Research
9/30/2025	$5.00	Buy → Neutral	Citigroup
9/29/2025	$8.00	Buy → Hold	Jefferies
9/29/2025		Buy → Neutral	BTIG Research
9/29/2025	$10.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

11/12/24 10:32:13 AM ET

$MLTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MLTX alert in real time by email

Recent Analyst Ratings for

$MLTX

Date	Price Target	Rating	Analyst
11/3/2025	$30.00	Neutral → Buy	H.C. Wainwright
10/2/2025		Buy → Neutral	H.C. Wainwright
10/1/2025	$7.00	Buy → Neutral	Goldman
9/30/2025	$2.00	Outperform → Underperform	Wolfe Research
9/30/2025	$5.00	Buy → Neutral	Citigroup
9/29/2025	$8.00	Buy → Hold	Jefferies
9/29/2025		Buy → Neutral	BTIG Research
9/29/2025	$10.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$MLTX

Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$MLTX

$MLTX
Insider Purchases

Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)

Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

$MLTX
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics

Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics

MoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$MLTX
Insider Trading

Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)

Former 10% Owner Chen Bihua sold $46,868,184 worth of Class A Ordinary Shares (6,499,978 units at $7.21) (SEC Form 4)

Chief Scientific Officer Reich Kristian converted options into 48,978 units of Class A ordinary shares and returned 48,978 units of Class C ordinary shares to the company, decreasing direct ownership by 77% to 35,389 units (SEC Form 4)

$MLTX
Press Releases

$MLTX
Analyst Ratings

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics upgraded by H.C. Wainwright with a new price target

MoonLake Immunotherapeutics downgraded by H.C. Wainwright

MoonLake Immunotherapeutics downgraded by Goldman with a new price target

$MLTX
Financials

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

$MLTX
Large Ownership Changes